Bowel Resection, Epstein-Barr Virus, Hemophagocytic Lymphohistiocytosis
Conditions
Brief summary
EBV-HLH is a rare disease with high mortality, especially for those with intestinal involvement. In order to reduce disease burden and improve survival of these patients, we conduct a prospective observational study to explore the efficacy and safety of segmental resection combined with the DEP regimen.
Detailed description
Epstein-Barr virus associated hemophagocytic lymphohistiocytosis is a rare disease with high mortality, especially for those with intestinal involvement. Some of them still died despite early control of the disease due to severe complications, such as gastrointestinal bleeding. In order to reduce disease burden and improve survival of these patients, we conduct a prospective observational study to explore the efficacy and safety of segmental resection combined with the DEP regimen.
Interventions
OTHERSegmental bowel resection combined with the DEP regimen
Segmental bowel resection combined with liposomal doxorubicin, etoposide, and methylprednisolone administered in 2 week cycles for 2 cycles
Sponsors
Beijing Friendship Hospital
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Met HLH-2004 diagnostic criteria; * EBV-DNA in the peripheral blood \> 1000 copies/ml or EBV-encoded small RNA (EBER) detected in tissues; * Imaging revealed severe intestinal lesions and biopsy confirmed EBV-encoded small RNA (EBER) in the tissues; * Age \>18 years old, gender is not limited; * Estimated survival time \> 1 month; * Informed consent obtained.
Exclusion criteria
* Active infections (viral, bacterial, fungal or parasitic); * Diagosed with malignant tumos within 5 years； * Uncontrolled symptoms or other diseases including, but not limited to, unstable angina pectoris, arrhythmia, respiratory failure, severe hepatic or renal insufficiency, severe coagulation dysfunction, mental illness, or other conditions deemed by the attending physician to be contraindications to surgery; * Heart function above grade II (NYHA); * Severe myocardial injury：TNT、TNI、CK-MB \> 3 ULN; * Accumulated dose of doxorubicin above 400mg/m2 、epirubicin above 750mg/m2、pirarubicin above 800mg/m2 or the patients treated with anthracycline induced cardiovascular disease; * Pregnancy or lactating Women; * Allergic to pegylated liposomal doxorubicin and etoposide; * HIV antibody positivity; * Acute or chronic active hepatitis B (HBsAg positivity, HBV DNA negative acceptable), acute or chronic active hepatitis C (HCV antibody negatively acceptable; HCV antibody positivity, HCV RNA negative acceptable); * Participate in other clinical research at the same time; * The researchers considered that patients are not suitable for the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| ORR | 4 Week | The percentage of cases that achieved complete response (CR) and partial response (PR) after treatment. |
| Adverse events | 1 month | Incidence of adverse reactions |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| OS | 1 years | Overall survival rate |
Countries
China
Contacts
Primary ContactZhao Wang, MD
Outcome results
None listed